Stock tip: This is how JP Morgan Chase & Co. rates QIAGEN shares

JP Morgan Chase & Co. has taken a close look at QIAGEN shares. Here are the resulting results.

According to figures, the US bank JPMorgan raised the price target for Qiagen from $50 to $52 and left the rating at “Overweight”. The outlook for the diagnostics specialist and laboratory service provider is below market expectations, but is achievable and sounds similar to that of other companies in the industry, analyst Casey Woodring wrote in a study available on Thursday. At least the targets for the current year appeared to be less risky than those of competitors.

From price target to trading volume: The QIAGEN share on the day of the detailed analysis

The QIAGEN stock rose at 1:51 p.m. and rose by 0.9 percent to EUR 40.90 in XETRA trading. The number of QIAGEN shares traded to date is 213,830. Since the beginning of 2024, the paper has increased by 0.7 percent.

NEW YORK (dpa-AFX Analyzer) / editorial team

Publication of the original study: February 7, 2024 / 4:31 p.m. / GMT
First distribution of the original study: February 7, 2024 / 4:31 p.m. / GMT

Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 Para. 1 WpHG, Art. 20 Regulation (EU) 596/2014 for the analyst firm mentioned can be found at disclosure_duty.html.

Selected leverage products on QIAGEN

With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on QIAGEN